Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Companies warn investors that DOGE’s federal cuts might hurt business
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...